Targeted therapy for LIMD1-deficient non-small cell lung cancer subtypes
Kathryn Davidson1, Paul Grevitt1, Maria F Contreras-Gerenas1
1Barts Cancer Institute, Queen Mary University of London, John Vane Science Centre, Charterhouse Square, London, EC1M6 BQ, UK.
Abstract:
An early event in lung oncogenesis is loss of the tumour suppressor gene LIMD1 (LIM domains containing 1); this encodes a scaffold protein, which suppresses tumorigenesis via a number of different mechanisms. Approximately 45% of non-small cell lung cancers (NSCLC) are deficient in LIMD1, yet this subtype of NSCLC has been overlooked in preclinical and clinical investigations. Defining therapeutic targets in these LIMD1 loss-of-function patients is difficult due to a lack of 'druggable' targets, thus alternative approaches are required. To this end, we performed the first drug repurposing screen to identify compounds that confer synthetic lethality with LIMD1 loss in NSCLC cells. PF-477736 was shown to selectively target LIMD1-deficient cells in vitro through inhibition of multiple kinases, inducing cell death via apoptosis. Furthermore, PF-477736 was effective in treating LIMD1-/- tumours in subcutaneous xenograft models, with no significant effect in LIMD1+/+ cells. We have identified a novel drug tool with significant preclinical characterisation that serves as an excellent candidate to explore and define LIMD1-deficient cancers as a new therapeutic subgroup of critical unmet need.
Insights
Loss of the LIMD1 tumor suppressor gene occurs in 45% of non-small cell lung cancers (NSCLC). Researchers identified PF-477736 as a drug that selectively kills LIMD1-deficient NSCLC cells, offering a new therapeutic strategy.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Loss of the LIMD1 tumor suppressor gene is an early event in lung oncogenesis.
- Approximately 45% of non-small cell lung cancers (NSCLC) exhibit LIMD1 deficiency, representing an understudied patient subgroup.
- Identifying therapeutic targets in LIMD1-deficient NSCLC is challenging due to a lack of druggable targets.
Purpose of the Study:
- To conduct the first drug repurposing screen to identify compounds exhibiting synthetic lethality with LIMD1 loss in NSCLC cells.
- To evaluate the efficacy of identified compounds in preclinical models of LIMD1-deficient NSCLC.
Main Methods:
- A drug repurposing screen was performed on NSCLC cells with varying LIMD1 status.
- In vitro assays were used to assess the selective toxicity of candidate compounds.
- Subcutaneous xenograft models were utilized to evaluate in vivo efficacy.
Main Results:
- PF-477736 selectively targeted and induced apoptosis in LIMD1-deficient NSCLC cells.
- PF-477736 demonstrated efficacy in reducing tumor growth in LIMD1-deficient xenograft models.
- No significant effect of PF-477736 was observed in LIMD1-proficient cells or tumors.
Conclusions:
- PF-477736 is a novel drug candidate that selectively targets LIMD1-deficient NSCLC.
- LIMD1-deficient cancers represent a distinct therapeutic subgroup with unmet clinical needs.
- Further exploration of PF-477736 is warranted for the treatment of LIMD1-deficient lung cancers.
More Related Videos
07:43Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:39lncRNA - Long Non-coding RNAs
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...